

# Rare Disease Clinical Trials Market - 2024-2033

<https://marketpublishers.com/r/RCC2C35CFB02EN.html>

Date: March 2026

Pages: 182

Price: US\$ 2,999.00 (Single User License)

ID: RCC2C35CFB02EN

## Abstracts

The Rare Disease Clinical Trials Market was valued at US\$ 13.43 Billion in 2024 and is anticipated to reach US\$ 30.13 Billion by 2033, at a CAGR of 0.0939 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Rare Disease Clinical Trials Market.

This report delivers a comprehensive overview of the Rare Disease Clinical Trials Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Rare Disease Clinical Trials Market. The Rare Disease Clinical Trials Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Rare Disease Clinical Trials Market Scope:

By Clinical Trials Phase

Phase I

Phase II

Phase III

Phase IV

#### By Therapeutic Area

Oncology

Neurology

Genetic Disorders

Hematology

Metabolic Disorders

Immunology

Others

#### By Study Design

Interventional

Observational

Expanded Access

Registry-based

#### By Sponsor

Pharmaceutical Companies

Biotechnology Companies

Contract Research Organizations (CROs)

Academic & Medical Research Institutes

Government & Public Health Organizations

Patient Advocacy Organizations

### By Patient Recruitment

Hospital-based

Patient Registry

Digital & Social Media

Community-based

Telehealth-enabled

### By Innovation

Biomarker based

Genomic based

Precision Medicine based

Cell & Gene Therapy based

Regenerative Medicine based

Proteomics based

Metabolomics based

Others

## Key Players

Takeda Pharmaceutical Company Limited

F. Hoffmann-La Roche Ltd.

Pfizer Inc.

AstraZeneca

Novartis AG

Labcorp

IQVIA

ICON plc

Parexel International (MA) Corporation

Syneos Health

## Major Highlights

This report delivers a comprehensive overview of the Rare Disease Clinical Trials Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Rare Disease Clinical Trials Market. The Rare Disease Clinical Trials Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

## Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

## Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

## Why Choose DataM?

**Data-Driven Insights:** Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

**Post-Purchase Support and Expert Analyst Consultations:** As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

**White Papers and Case Studies:** Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

**Annual Updates on Purchased Reports:** As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

**Specialized Focus on Emerging Markets:** DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

**Value of DataM Reports:** Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

## Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

## Contents

### 1. DEFINITION AND OVERVIEW

- 1.1. Study Objectives
- 1.2. Market Definition
- 1.3. Market Scope
- 1.4. Stakeholder Analysis
- 1.5. Currency Considered
- 1.6. Study Period

### 2. EXECUTIVE SUMMARY

- 2.1. Key Takeaways
- 2.2. Top To Bottom Analysis
- 2.3. Market Share Analysis
- 2.4. Data Points from Key Primary Interviews
- 2.5. Data Points from Key Secondary Databases
- 2.6. Market Snapshot
- 2.7. Geographical Snapshot

### 3. DYNAMICS

#### 3.1. Impacting Factors

##### 3.1.1. Drivers

- 3.1.1.1. Rising prevalence and improved diagnosis of rare diseases globally
- 3.1.1.2. Increasing investment in orphan drug and advanced therapy development
- 3.1.1.3. Growth in precision medicine, biomarker research, and genomic-based

clinical studies

##### 3.1.2. Restraints

3.1.2.1. Difficulty in patient recruitment due to small and geographically dispersed patient populations

- 3.1.2.2. High clinical trial costs and long development timelines

##### 3.1.3. Opportunity

- 3.1.3.1. Expansion of gene therapy and cell therapy clinical research
- 3.1.3.2. Increasing adoption of decentralized and patient-centric clinical trial models
- 3.1.3.3. Growth in public-private partnerships and rare disease research

collaborations

##### 3.1.4. Trends

- 3.1.4.1. Increasing use of artificial intelligence and real-world evidence in trial design and patient identification
- 3.1.4.2. Rising focus on adaptive trial designs and platform-based clinical studies
- 3.1.5. Impact Analysis

## **4. INDUSTRY ANALYSIS**

- 4.1. Porter's Five Force Analysis – Global Rare Disease Clinical Trials Market
- 4.2. Geopolitical & Supply Chain Exposure
  - 4.2.1. Clinical Trial Infrastructure and Site Concentration Risks
  - 4.2.2. Regulatory and Cross-Border Patient Enrollment Challenges
  - 4.2.3. Data Sovereignty and Clinical Data Transfer Restrictions
- 4.3. Social & Patient-Centric Factors
  - 4.3.1. Patient Recruitment Challenges in Rare Disease Populations
  - 4.3.2. Patient Advocacy Group Influence on Trial Design
  - 4.3.3. Treatment Access and Trial Participation Awareness
- 4.4. Economic Factors
  - 4.4.1. High R&D Cost Structure for Rare Disease Therapeutics
  - 4.4.2. Funding Dependence on Pharma, Government, and Grants
  - 4.4.3. Currency Fluctuations Impacting Global Trial Operations
- 4.5. Pricing Analysis
  - 4.5.1. Orphan Drug Pricing Models
  - 4.5.2. Clinical Trial Funding and Partnership Agreements
  - 4.5.3. Value-Based Pricing and Reimbursement Dependencies
- 4.6. Regulatory Analysis
  - 4.6.1. Orphan Drug Designation Pathways
  - 4.6.2. Accelerated Approval and Breakthrough Therapy Pathways
  - 4.6.3. Post-Trial Safety Monitoring and Pharmacovigilance
  - 4.6.4. Global Regulatory Harmonization
- 4.7. Go-To-Market (GTM) Strategy
  - 4.7.1. Strategic Partnerships with Hospitals and Specialty Centers
- 4.8. Innovation & R&D Trends
  - 4.8.1. Gene Therapy and Cell Therapy Clinical Development
  - 4.8.2. Precision Medicine and Biomarker-Driven Trials
  - 4.8.3. Real-World Evidence Integration in Trial Design
- 4.9. Sustainability and ESG Analysis
  - 4.9.1. Ethical Patient Recruitment Practices
  - 4.9.2. Diversity and Inclusion in Clinical Trial Populations
- 4.10. Clinical Trial Ecosystem Participants

- 4.10.1. Pharmaceutical and Biotech Sponsors
- 4.10.2. Contract Research Organizations
- 4.10.3. Diagnostic and Biomarker Testing Providers
- 4.10.4. Hospitals, Specialty Clinics, and Research Institutes
- 4.11. Buyer Decision Criteria & Adoption Drivers
  - 4.11.1. Access to Rare Disease Patient Populations
  - 4.11.2. Clinical Expertise in Complex Disease Biology
  - 4.11.3. Advanced Scientific Capabilities and Trial Success Rates
- 4.12. DMI Opinion – Strategic Outlook for the Global Rare Disease Clinical Trials Market

## **5. BY CLINICAL TRIALS PHASE**

- 5.1. Introduction
  - 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical Trials Phase
  - 5.1.2. Market Attractiveness Index, By Clinical Trials Phase
- 5.2. Phase I\*
  - 5.2.1. Introduction
  - 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 5.3. Phase II
- 5.4. Phase III
- 5.5. Phase IV

## **6. BY THERAPEUTIC AREA**

- 6.1. Introduction
  - 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
  - 6.1.2. Market Attractiveness Index, By Therapeutic Area
- 6.2. Oncology\*
  - 6.2.1. Introduction
  - 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Neurology
- 6.4. Genetic Disorders
- 6.5. Hematology
- 6.6. Metabolic Disorders
- 6.7. Immunology
- 6.8. Others

## **7. BY STUDY DESIGN**

## 7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Design

7.1.2. Market Attractiveness Index, By Study Design

## 7.2. Interventional \*

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

## 7.3. Observational

## 7.4. Expanded Access

## 7.5. Registry-based

# 8. BY SPONSOR

## 8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sponsor

8.1.2. Market Attractiveness Index, By Sponsor

## 8.2. Pharmaceutical Companies\*

8.2.1. Introduction

8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

## 8.3. Biotechnology Companies

## 8.4. Contract Research Organizations (CROs)

## 8.5. Academic & Medical Research Institutes

## 8.6. Government & Public Health Organizations

## 8.7. Patient Advocacy Organizations

# 9. BY PATIENT RECRUITMENT

## 9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Recruitment

9.1.2. Market Attractiveness Index, By Patient Recruitment

## 9.2. Hospital-based \*

9.2.1. Introduction

9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

## 9.3. Patient Registry

## 9.4. Digital & Social Media

## 9.5. Community-based

## 9.6. Telehealth-enabled

# 10. BY INNOVATION

## 10.1. Introduction

10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Innovation

10.1.2. Market Attractiveness Index, By Innovation

## 10.2. Biomarker based \*

10.2.1. Introduction

10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

## 10.3. Genomic based

## 10.4. Precision Medicine based

## 10.5. Cell & Gene Therapy based

## 10.6. Regenerative Medicine based

## 10.7. Proteomics based

## 10.8. Metabolomics based

## 10.9. Others

# 11. BY REGION

## 11.1. Introduction

11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

11.1.2. Market Attractiveness Index, By Region

## 11.2. North America

11.2.1. Introduction

11.2.2. Key Region-Specific Dynamics

11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical Trials Phase

11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area

11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Design

11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sponsor

11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Recruitment

11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Innovation

11.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11.2.9.1. US

11.2.9.2. Canada

11.2.9.3. Mexico

## 11.3. Europe

11.3.1. Introduction

11.3.2. Key Region-Specific Dynamics

11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical Trials Phase

11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area

11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Design

11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sponsor

- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Recruitment
- 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Innovation
- 11.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.9.1. Germany
  - 11.3.9.2. United Kingdom
  - 11.3.9.3. France
  - 11.3.9.4. Italy
  - 11.3.9.5. Spain
  - 11.3.9.6. Netherlands
  - 11.3.9.7. Switzerland
  - 11.3.9.8. Sweden
  - 11.3.9.9. Norway
  - 11.3.9.10. Denmark
  - 11.3.9.11. Belgium
  - 11.3.9.12. Poland
  - 11.3.9.13. Austria
  - 11.3.9.14. Ireland
  - 11.3.9.15. Portugal
  - 11.3.9.16. Greece
  - 11.3.9.17. Finland
  - 11.3.9.18. Rest of Europe
- 11.4. Latin America
  - 11.4.1. Introduction
  - 11.4.2. Key Region-Specific Dynamics
  - 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical Trials Phase
  - 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
  - 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Design
  - 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sponsor
  - 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Recruitment
  - 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Innovation
  - 11.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    - 11.4.9.1. Brazil
    - 11.4.9.2. Argentina
    - 11.4.9.3. Mexico
    - 11.4.9.4. Chile
    - 11.4.9.5. Colombia
    - 11.4.9.6. Peru
    - 11.4.9.7. Rest of Latin America
- 11.5. Asia-Pacific

- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical Trials Phase
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Design
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sponsor
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Recruitment
- 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Innovation
- 11.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.9.1. China
  - 11.5.9.2. Japan
  - 11.5.9.3. India
  - 11.5.9.4. South Korea
  - 11.5.9.5. Australia
  - 11.5.9.6. New Zealand
  - 11.5.9.7. Singapore
  - 11.5.9.8. Malaysia
  - 11.5.9.9. Thailand
  - 11.5.9.10. Indonesia
  - 11.5.9.11. Vietnam
  - 11.5.9.12. Philippines
  - 11.5.9.13. Taiwan
  - 11.5.9.14. Rest of Asia Pacific
- 11.6. Middle East and Africa
  - 11.6.1. Introduction
  - 11.6.2. Key Region-Specific Dynamics
  - 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical Trials Phase
  - 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
  - 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Design
  - 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sponsor
  - 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Recruitment
  - 11.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Innovation
  - 11.6.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    - 11.6.9.1. Saudi Arabia
    - 11.6.9.2. United Arab Emirates
    - 11.6.9.3. Qatar
    - 11.6.9.4. Kuwait
    - 11.6.9.5. Oman
    - 11.6.9.6. Bahrain

- 11.6.9.7. South Africa
- 11.6.9.8. Egypt
- 11.6.9.9. Nigeria
- 11.6.9.10. Morocco
- 11.6.9.11. Rest of Middle East & Africa

## **12. COMPETITIVE LANDSCAPE ANALYSIS**

- 12.1. Competitive Scenario
- 12.2. Market Positioning/Share Analysis
- 12.3. Mergers and Acquisitions Analysis
- 12.4. Partner Identification Analysis
- 12.5. Investment & Funding Landscape
- 12.6. Strategic Alliances & Innovation Pipelines

## **13. COMPANY PROFILES**

- 13.1. Takeda Pharmaceutical Company Limited\*
  - 13.1.1. Company Overview
  - 13.1.2. Product Portfolio
  - 13.1.3. Revenue Analysis
  - 13.1.4. Pricing Analysis
  - 13.1.5. SWOT Analysis
  - 13.1.6. Recent Developments
    - 13.1.6.1. Major Deals
    - 13.1.6.2. M&A
    - 13.1.6.3. Collaboration
    - 13.1.6.4. Acquisition
    - 13.1.6.5. Joint Ventures
    - 13.1.6.6. Innovations
  - 13.1.7. Recent News
    - 13.1.7.1. Events
    - 13.1.7.2. Conferences
    - 13.1.7.3. Symposiums
    - 13.1.7.4. Webinars
- 13.2. F. Hoffmann-La Roche Ltd.
- 13.3. Pfizer Inc.
- 13.4. AstraZeneca
- 13.5. Novartis AG

- 13.6. Labcorp
- 13.7. IQVIA
- 13.8. ICON plc
- 13.9. Parexel International (MA) Corporation
- 13.10. Syneos Health (LIST NOT EXHAUSTIVE )

## **14. GLOBAL RARE DISEASE CLINICAL TRIALS MARKET – RESEARCH METHODOLOGY**

- 14.1. Research Data
  - 14.1.1. Secondary Data
  - 14.1.2. Primary Data
  - 14.1.3. CAGR Analysis
- 14.2. Market Size Estimation Methodology
  - 14.2.1. Bottom-Up Approach
  - 14.2.2. Top-Down Approach
- 14.3. Market Breakdown & Data Triangulation
- 14.4. Research Assumptions
- 14.5. Limitations

## **15. APPENDIX**

- 15.1. About Us and Services
- 15.2. Contact Us

## I would like to order

Product name: Rare Disease Clinical Trials Market - 2024-2033

Product link: <https://marketpublishers.com/r/RCC2C35CFB02EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RCC2C35CFB02EN.html>